Clinical impact of MDR1-expression in testicular germ cell cancer

Experimental Oncology

Volumn 29, Issue 3, 2007, Pages 212-216

  Schrader, A J ^a   Seger, M ^a   Konrad, L ^a   Olbert, P ^a   Hegele, A ^a   Hofmann, R ^a   Heidenreich, A ^a  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

Author keywords

NSGCT; P gp; p170; RPLND; Seminoma; Teratoma; Testis; Tumor

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MULTIDRUG RESISTANCE PROTEIN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROGNOSIS; PROTEIN EXPRESSION; TERATOMA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; P-GLYCOPROTEIN; PROGNOSIS; RETROPERITONEAL NEOPLASMS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 36749021188     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-99.
2. IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
3. de Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78: 828-32.
4. Schrader AJ, Ohlmann CH, Rossmanith S, Hofmann R, Heidenreich A. Impact of evidence-based interdisciplinary guidelines on testis cancer management. Cancer 2006; 106: 313-9.
5. Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 1997; 80: 653-7.
6. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994; 74: 1329-34.
7. Wood DP, Jr, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992; 148: 1812-5; discussion 1815-6.
8. Oldenburg J, Alfsen GC, Den HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21: 3310-7.
9. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
10. Savitskiy VP, Zorin VP, Potapnev MP. Accumulation of chlorine e6 derivatives in cells with different level of expression and function activity of multidrug resistance protein P-gp 170. Exp Oncol 2005; 27: 47-51.
11. Eid H, Bodrogi I, Csokay B, Olah E, Bak M. Multidrug resistance of testis cancers: the study of clinical relevance of P-glycoprotein expression. Anticancer Res 1996; 16: 3447-52.
12. Eid H, Geczi L, Magori A, Bodrogi I, Institoris E, Bak M. Drug resistance and sensitivity of germ cell testicular tumors: evaluation of clinical relevance of MDR1/Pgp, p53, and metallothionein (MT) proteins. Anticancer Res 1998; 18: 3059-64.
13. Guidelines on the management of adult testicular cancer. Clin Oncol (R Coll Radiol) 2000; 12: S173-210.
14. Takada Y, Kobayashi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 2005; 280: 17203-12.
15. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
16. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987; 262: 505-8.
17. Stefkova J, Poledne R, Hubacek JA. ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res 2004; 53: 235-43.
18. Mahadevan D, Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 2005; 5: 445-55.
19. Labialle S, Dayan G, Michaud M, Barakat S, Rigal D, Baggetto LG. Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope? Semin Oncol 2005; 32: 583-90.
20. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006; 12: 273-86.
21. Katagiri A, Tomita Y, Nishiyama T, Kimura M, Sato S. Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer. Br J Cancer 1993; 68: 125-9.
22. Baran Y, Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol 2006; 28: 163-5.